9 results on '"Piek, Arnold"'
Search Results
2. Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling
- Author
-
Piek, Arnold, Koonen, Debby P. Y., Schouten, Elisabeth-Maria, Lindtstedt, Eva L., Michaëlsson, Erik, de Boer, Rudolf A., and Silljé, Herman H. W.
- Published
- 2019
- Full Text
- View/download PDF
3. Abstract 20437: Circulating Levels of Galectin-3, Gdf-15 and Timp1 in Heart Failure Are Predominantly From Non-Cardiac Sources
- Author
-
Piek, Arnold, Du, Weijie, de Boer, Rudolf A, and Sillje, Herman H
- Published
- 2017
4. A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
- Author
-
Piek, Arnold, Suthahar, Navin, Voors, Adriaan A., Boer, Rudolf A., and Silljé, Herman H.W.
- Subjects
- *
BRAIN natriuretic factor , *BIOMARKERS , *HEART failure , *NATRIURETIC peptides , *PROGNOSIS , *ATRIAL fibrillation - Abstract
Aims: Cardiac specificity provides an advantage in correlating heart failure (HF) biomarker plasma levels with indices of cardiac function and remodelling, as shown for natriuretic peptides. Using bioinformatics, we explored the cardiac specificity of secreted proteins and investigated in more detail the relationship of Dickkopf‐3 (DKK3) gene expression and DKK3 plasma concentrations with cardiac function and remodelling in (pre)clinical studies. Methods and results: The cardiac specificity of secreted proteins was determined using RNAseq data for a large panel of organs and tissues. This showed that natriuretic peptides (NPPA and NPPB) are highly cardiac‐specific (>99%), whereas other HF biomarkers, including galectin‐3 (Gal‐3, LGALS3) and growth differentiation factor‐15 (GDF‐15), lack cardiac specificity (<4%). DKK3 was cardiac‐enriched (44%), warranting further investigation. In three different HF mouse models, cardiac Dkk3 expression was altered, but DKK3 plasma concentrations were not. In humans, DKK3 plasma concentrations were higher in HF patients (n = 2090) in comparison with age‐ and sex‐matched controls without HF (n = 240) (46.4 ng/mL vs. 36.3 ng/mL; P < 0.001). Multivariate regression analysis revealed that DKK3 was strongly associated with HF risk factors and comorbidities, including age, kidney function and atrial fibrillation. After correction for existing prediction models, DKK3 did not independently predict HF outcome [all‐cause mortality/HF hospitalization, hazard ratio 1.13 (0.79–1.61) per DKK3 doubling; P = 0.503]. Conclusions: Of actively secreted HF biomarkers, only natriuretic peptides showed high cardiac specificity. Despite a cardiac specificity of 44%, secreted DKK3 had limited additional diagnostic and prognostic value. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. A novel method optimizing the normalization of cardiac parameters in small animal models: the importance of dimensional indexing.
- Author
-
Hagdorn, Quint A. J., Bossers, Guido P. L., Koop, Anne-Marie C., Piek, Arnold, Eijgenraam, Tim R., van der Feen, Diederik E., Silljé, Herman H. W., de Boer, Rudolf A., and Berger, Rolf M. F.
- Subjects
ANIMAL models in research ,BODY weight ,INDEXING - Abstract
For indexing cardiac measures in small animal models, tibia length (TL) is a recommended surrogate for body weight (BW) that aims to avoid biases because of disease-induced BW changes. However, we question if indexing by TL is mathematically correct. This study aimed to investigate the relation between TL and BW, heart weight, ventricular weights, and left ventricular diameter to optimize the current common practice of indexing cardiac parameters in small animal models. In 29 healthy Wistar rats (age 5-34 wk) and 116 healthy Black 6 mice (age 3-17 wk), BW appeared to scale nonlinearly to TL
1 but linearly to TL3 . Formulas for indexing cardiac weights were derived. To illustrate the effects of indexing, cardiac weights between the 50% with highest BW and the 50% with lowest BW were compared. The nonindexed cardiac weights differed significantly between groups, as could be expected (P < 0.001). However, after indexing by TL1 , indexed cardiac weights remained significantly different between groups (P < 0.001). With the derived formulas for indexing, indexed cardiac weights were similar between groups. In healthy rats and mice, BW and heart weights scale linearly to TL3 . This indicates that not TL1 but TL3 is the optimal surrogate for BW. New formulas for indexing heart weight and isolated ventricular weights are provided, and we propose a concept in which cardiac parameters should not all be indexed to the same measure but one-dimensional measures to BW1/3 or TL1 , twodimensional measures to BW2/3 or TL2 , and three-dimensional measures to BW or TL3 . [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Novel heart failure biomarkers: why do we fail to exploit their potential?
- Author
-
Piek, Arnold, Du, Weijie, de Boer, Rudolf A., and Silljé, Herman H. W.
- Subjects
- *
HEART failure , *ANTIGENS , *BIOMARKERS , *CALCITONIN , *CELL death , *CYTOKINES , *FATTY acid-binding proteins , *GLUTAMIC acid , *HETEROCYCLIC compounds , *INFLAMMATION , *INTERLEUKINS , *PEPTIDE hormones , *RNA , *FIBROSIS , *ACYCLIC acids , *NATRIURETIC peptides , *TROPONIN , *DIAGNOSIS - Abstract
Plasma biomarkers are useful tools in the diagnosis and prognosis of heart failure (HF). In the last decade, numerous studies have aimed to identify novel HF biomarkers that would provide superior and/or additional diagnostic, prognostic, or stratification utility. Although numerous biomarkers have been identified, their implementation in clinical practice has so far remained largely unsuccessful. Whereas cardiac-specific biomarkers, including natriuretic peptides (ANP and BNP) and high sensitivity troponins (hsTn), are widely used in clinical practice, other biomarkers have not yet proven their utility. Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (sST2) are the only novel HF biomarkers that are included in the ACC/AHA HF guidelines, but their clinical utility still needs to be demonstrated. In this review, we will describe natriuretic peptides, hsTn, and novel HF biomarkers, including Gal-3, sST2, human epididymis protein 4 (HE4), insulin-like growth factor-binding protein 7 (IGFBP-7), heart fatty acid-binding protein (H-FABP), soluble CD146 (sCD146), interleukin-6 (IL-6), growth differentiation factor 15 (GDF-15), procalcitonin (PCT), adrenomedullin (ADM), microRNAs (miRNAs), and metabolites like 5-oxoproline. We will discuss the biology of these HF biomarkers and conclude that most of them are markers of general pathological processes like fibrosis, cell death, and inflammation, and are not cardiac- or HF-specific. These characteristics explain to a large degree why it has been difficult to relate these biomarkers to a single disease. We propose that, in addition to clinical investigations, it will be pivotal to perform comprehensive preclinical biomarker investigations in animal models of HF in order to fully reveal the potential of these novel HF biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure.
- Author
-
Piek, Arnold, Meijers, Wouter C., Schroten, Nicolas F., Gansevoort, Ron T., de Boer, Rudolf A., and Silljé, Herman H.W.
- Abstract
Background: The novel biomarker human epididymis protein 4 (HE4) shows prognostic value in acute heart failure (HF) patients. We measured HE4 levels in patients with chronic heart failure (CHF) and correlated them to HF severity, kidney function, and HF biomarkers, and determined its predictive value.Methods: Serum HE4 levels in patients (n = 101) with stable CHF with reduced left ventricular ejection fraction (LVEF <45%) from the Vitamin D CHF (VitD-CHF) study (NCT01092130) were compared with those in age- and sex-matched healthy control subjects (n = 58) from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study.Results: HE4 levels were higher in CHF compared with control subjects (69.2 pmol/L [interquartile range 55.6-93.8] vs 56.1 pmol/L [46.6-69.0]; P < .001) and were higher with increasing New York Heart Association functional class. Levels were associated with HF risk factors, including age, gender, diabetes, smoking and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). HE4 demonstrated strong associations with kidney function and HF fibrosis biomarkers. In a multivariable model, we identified creatinine, NT-proBNP, galectin-3, high-sensitive troponin T, and smoking as factors associated with HE4. Independently from these factors, HE4 levels predicted death and HF rehospitalization (5-year follow-up, hazard ratio 3.8; confidence interval 1.31-11.1; P = .014).Conclusions: HE4 levels are increased in CHF, correlate with HF severity and kidney function, and predict HF outcome. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. The vicious cycle of arrhythmia and myocardial fibrosis.
- Author
-
Piek, Arnold, Silljé, Herman H.W., and de Boer, Rudolf A.
- Subjects
- *
ARRHYTHMIA , *FIBROSIS , *FLECAINIDE , *CONNECTIVE tissue growth factor , *TRANSFORMING growth factors-beta , *CELLS , *GROWTH factors , *HEART failure - Published
- 2019
- Full Text
- View/download PDF
9. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.
- Author
-
Du W, Piek A, Schouten EM, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, and Silljé HHW
- Subjects
- Animals, Atrial Natriuretic Factor analysis, Atrial Natriuretic Factor blood, Biomarkers analysis, Disease Models, Animal, Galectin 3 analysis, Galectin 3 blood, Growth Differentiation Factor 15 analysis, Growth Differentiation Factor 15 blood, Mice, Tissue Inhibitor of Metalloproteinase-1 analysis, Tissue Inhibitor of Metalloproteinase-1 blood, Biomarkers blood, Heart Failure diagnosis, Heart Failure pathology, Plasma chemistry
- Abstract
Plasma heart failure (HF) biomarkers, like natriuretic peptides, are important in diagnosis, prognosis and HF treatment. Several novel HF biomarkers have been identified, including Gal-3, GDF-15 and TIMP-1, but their clinical potential remains vague. Here we investigated plasma biomarker levels in relation to tissue expression and structural and functional cardiac changes. Methods: Cardiac remodeling, cardiac function, and plasma and tissue biomarker levels were investigated in mice after myocardial infarction induced by temporal and permanent LAD ligation (tLAD and pLAD). In addition, a pressure overload model induced by transverse aortic constriction (TAC) and an obese/hypertensive HFpEF-like mouse model were investigated. Results: Plasma levels of ANP and its cardiac expression were strictly associated with cardiac remodeling and function. Gal-3, GDF-15 and TIMP-1 cardiac expressions were also related to cardiac remodeling and function, but not their plasma levels. Only directly after myocardial infarction could elevated plasma levels of Gal-3 and TIMP-1 be detected. Eight weeks after infarction, plasma levels were not elevated despite enhanced cardiac expression and low EF (18.3±3.3%, pLAD). Plasma levels of TIMP-1 and GDF-15 were elevated after TAC, but this also correlated with increased lung expression and congestion. In obese-hypertensive mice, elevated plasma levels of Gal-3, GDF-15 and TIMP1 were associated with increased adipose tissue expression and not with cardiac function. Conclusions: The Gal-3, GDF-15 and TIMP-1 plasma pool levels are hardly influenced by dynamic changes in cardiac expression. These biomarkers are not specific for indices of cardiac remodeling, but predominantly reflect stress in other affected tissues and hence provide health information beyond the heart., Competing Interests: Competing Interests: The UMCG, which employs a number of the authors, received research grants and consultancy fees from AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Trevena, Thermofisher GmbH, and Sphingotec GmbH, for work done by UMCG employers. Dr. Voors received funding from Roche Diagnostics and Sphingotec. Dr. de Boer received speaker fees from Novartis. Dr. H. Silljé received research grants from AstraZeneca.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.